China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-04	US$0.1231	+60.08%	168,696,003
26-08-03	US$0.0769	+24.34%	434,073,899
26-07-31	US$0.0618	-15.39%	61,302,929
26-07-30	US$0.0731	+39.24%	540,742,709
26-07-29	US$0.0525	-8.85%	58,637,624

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-04 EDT			5-day change	1st Jan Change
0.1231 ^USD	+60.08%		+113.72%	-99.95%

07-30	Top Premarket Gainers	MT
07-28	Top Premarket Decliners	MT

Market Cap	4.04M 3.51M 3.27M 3.01M 5.69M 385M 5.75M 38.59M 15.09M 192M 15.18M 14.85M 637M	P/E 2025 *	-	P/E 2026	-0.18x
Enterprise Value	-23.16M -20.11M -18.75M -17.22M -32.57M -2.2B -32.93M -221M -86.4M -1.1B -86.96M -85.05M -3.65B	EV / Sales 2025	9.81x	EV / Sales 2026	-22.6x
Free-Float	17.43%	Yield 2025 *	-	Yield 2026	-

07-30	Top Premarket Gainers	MT
07-28	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT
07-23	Top Premarket Decliners	MT
07-22	Top Premarket Gainers	MT
07-02	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
12-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
25-07-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-03-28	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
25-03-17	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT
25-01-23	China SXT Pharmaceuticals, Inc. Announces CEO Changes	CI

07-24	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
07-23	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
07-01	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
01-30	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1650

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Analysts' recommendations: China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+60.08%
1 week	+113.72%
Current month	+99.03%
1 month	-94.98%
3 months	-94.05%
6 months	-96.88%
Current year	-99.95%

1 week	0.05	0.13
1 month	0.05	2.85
Current year	0.05	1,046.98
1 year	0.05	1,046.98
3 years	0.05	11,249.94
5 years	0.05	839,983.2
10 years	0.05	56,035,517.16

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	2025-01-19
Feng Zhou CEO	Chief Executive Officer	34	2017-07-03
Xiaodong Pan DFI	Director of Finance/CFO	49	2022-01-30

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	2017-07-03
Jun Zheng BRD	Director/Board Member	49	2018-12-30
Xiaodong Ji BRD	Director/Board Member	57	2021-05-21

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	+60.08%	+113.72%	-99.95%	-100.00%	3.97M
ELI LILLY AND COMPANY	-0.51%	-8.60%	+45.08%	+148.21%	995B
JOHNSON & JOHNSON	+0.20%	-4.42%	+49.05%	+50.81%	614B
ABBVIE INC.	-0.53%	-7.37%	+23.64%	+65.03%	431B
ROCHE HOLDING AG	+0.48%	-2.77%	+40.27%	+34.96%	353B
NOVARTIS AG	+0.08%	-4.45%	+31.74%	+39.89%	293B
ASTRAZENECA PLC	+2.09%	-9.27%	+5.42%	+7.61%	245B
NOVO NORDISK A/S	+1.75%	-8.29%	-1.73%	-42.05%	210B
AMGEN INC.	+2.94%	-0.78%	+29.17%	+60.32%	210B
GILEAD SCIENCES, INC.	+3.13%	+0.69%	+18.11%	+71.90%	168B
Average	+7.07%	+6.85%	+14.08%	+33.67%	351.82B
Weighted average by Cap.	+0.74%	-5.89%	+33.77%	+70.63%

	2025	2026
Net sales	1.74M 1.51M 1.41M 1.29M 2.45M 166M 2.48M 16.62M 6.5M 82.78M 6.54M 6.39M 274M	1.14M 988K 921K 846K 1.6M 108M 1.62M 10.86M 4.25M 54.11M 4.27M 4.18M 179M
Net income	-3.3M -2.87M -2.67M -2.46M -4.65M -314M -4.7M -31.53M -12.33M -157M -12.41M -12.13M -521M	-6.21M -5.39M -5.02M -4.61M -8.73M -590M -8.82M -59.23M -23.15M -295M -23.3M -22.79M -978M
Net Debt	-17.25M -14.98M -13.97M -12.83M -24.27M -1.64B -24.53M -165M -64.37M -820M -64.79M -63.37M -2.72B	-27.2M -23.62M -22.02M -20.23M -38.26M -2.59B -38.68M -260M -101M -1.29B -102M -99.91M -4.29B